Plus   Neg

Stock Alert: Cassava Sciences To Report Q4 Results Today

Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, that develops drugs for nervous system disorders, is scheduled to report its fourth-quarter results today, March 23.

On average, analysts polled by Thomson Reuters expect the company to report loss of $0.13 per share.

In the third-quarter, the company had a positive earnings surprise of $0.04 loss per share compared with loss per share of $0.13 during the corresponding period last year.

The company's lead drug candidate is PTI-125 proposed for the treatment of Alzheimer's disease is in phase IIb study. Cassava expects to announce top-line results by mid-year 2020.

Cassava is also developing PTI-125Dx, a blood-based diagnostic to detect and monitor Alzheimer's disease.

The company, as a rule, gives updates on clinical trials during quarterly results.

Cassava Sciences ended the third quarter with $17.8 million of cash and equivalents, and no debt.

SAVA was down $0.36 or 8.51% on March 20, before closing at $3.87. It has traded in the range of $1.00- $10.95 in the last 52-weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT